List view / Grid view
Despite some challenges, for the Alzheimer’s drug development pipeline, 2024…
Despite some challenges, for the Alzheimer’s drug development pipeline, 2024 is a “learning year”, an expert on the disease says.
Top-line Phase IIa data has demonstrated an allogeneic stem-cell therapy…
Top-line Phase IIa data has demonstrated an allogeneic stem-cell therapy facilitated a lack of deterioration in cognitive signals in mild Alzheimer’s.
Neflamapimod taken three times a day significantly improved cognition in…
Neflamapimod taken three times a day significantly improved cognition in trial participants with mild-to-moderate dementia with Lewy bodies (DLB).
